4717. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
作者: Silvio Danese.;Séverine Vermeire.;Wen Zhou.;Aileen L Pangan.;Jesse Siffledeen.;Susan Greenbloom.;Xavier Hébuterne.;Geert D'Haens.;Hiroshi Nakase.;Julian Panés.;Peter D R Higgins.;Pascal Juillerat.;James O Lindsay.;Edward V Loftus.;William J Sandborn.;Walter Reinisch.;Min-Hu Chen.;Yuri Sanchez Gonzalez.;Bidan Huang.;Wangang Xie.;John Liu.;Michael A Weinreich.;Remo Panaccione.
来源: Lancet. 2022年399卷10341期2113-2128页
There is a great unmet need for advanced therapies that provide rapid, robust, and sustained disease control for patients with ulcerative colitis. We assessed the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis.
|